Clinical Trial Update: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial evaluating vismodegib with RO4929097 targeting Hedgehog and Notch pathways in various advanced/metastatic soft tissue sarcomas; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Soft Part Sarcoma
• Angiosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• RO4929097 (RO4929097)
• Vismodegib (Vismodegib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-07-22